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Abstract 16 
SETD5 gene mutations have been identified as a frequent cause of idiopathic 17 
intellectual disability. Here we show that Setd5 haploinsufficient mice present 18 
developmental defects such as abnormal brain to body weight ratio and neural crest 19 
defect associated phenotypes. Furthermore, Setd5 mutant mice show impairments in 20 
cognitive tasks, enhanced long-term potentiation, delayed ontogenetic profile of 21 
ultrasonic vocalisation and behavioural inflexibility. Behavioural issues are 22 
accompanied by abnormal expression of postsynaptic density proteins previously 23 
associated with cognition. Our data additionally indicate that Setd5 regulates RNA 24 
polymerase II dynamics and gene transcription via its interaction with the Hdac3 and 25 
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Paf1 complexes, findings potentially explaining the gene expression defects 26 
observed in Setd5 haploinsufficient mice. Our results emphasize the decisive role of 27 
Setd5 in a biological pathway found to be disrupted in intellectual disability and 28 
autism spectrum disorder patients. 29 
 30 
Main  31 
Intellectual disability (ID), characterized by substantial limitation of cognitive 32 
functions and adaptive behaviours, affects 1.5-2 % of the Western population1. ID 33 
often co-exists with core symptoms of autism spectrum disorders (ASD), such as 34 
impairment in social interaction, communication and presence of repetitive 35 
behaviours1.  ID and ASD have a strong genetic component and several ID- and 36 
ASD-genes have been identified2,3. 37 
The SET-domain containing 5 (SETD5) gene belongs to the SET-domain 38 
containing gene family, encoding histone-modifying proteins4. De novo mutations in 39 
the SETD5 gene have been recently identified as a cause of ID and ASD with up to 40 
0.7% of patients with idiopathic ID carrying heterozygous mutations in the SETD5 41 
gene5,6. While the number of reported cases increases, allowing the delineation of a 42 
"SETD5 syndrome"7,8, SETD5’s molecular function and role in cognition remain 43 
elusive. 44 
Here, we show that Setd5 haploinsufficiency in mice leads to embryonic 45 
development defects and behavioural abnormalities. Developmental and behavioural 46 
issues correlate with abnormal control of gene expression in embryonic and adult 47 
mutant animals. Particularly, we found that disruption of Setd5 impairs the proper 48 
expression of a number of post-synaptic density proteins implicated in synaptic 49 
plasticity and learning. At the molecular level Setd5 interacts with the histone 50 
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deacetylase 3 (Hdac3) and polymerase-associated factor 1 (Paf1) complexes to 51 
regulate gene transcription. Intriguingly, several components of the HDAC3 and 52 
PAF1 complexes have been previously involved in ID and ASD.  53 
 54 
Results 55 
Setd5 haploinsufficiency leads to early developmental defects.  56 
Setd5 is expressed in several tissues, including the brain, during development 57 
and in adulthood6,9. To examine the effect of Setd5 haploinsufficiency in vivo, we 58 
studied Setd5+/- mice (Supplementary Fig. 1). While full deletion of Setd5 leads to 59 
lethality at early embryonic stages9, Setd5+/- mice are viable but born at a non-60 
Mendelian rate (Supplementary Fig. 2a) and have lower survival probability 61 
(Supplementary Fig. 2b). Interestingly, newborn and adult mutant mice present with 62 
increased brain to body weight ratio (Fig. 1a and Supplementary Fig. 2c) suggesting 63 
developmental defects. Many Setd5+/- mice also display tooth displacement, eye 64 
problems, white spotting of the belly and craniofacial abnormalities (Fig. 1b-c and 65 
Supplementary Fig. 2d-e), issues linked to aberrant head and trunk neural crest 66 
proliferation and cell fate determination10,11. These features, in part also observed in 67 
patients with SETD5 mutations5-7, suggest that Setd5 haploinsufficiency may impact 68 
developmental processes at very early stages.  69 
Following these observations, we performed RNA sequencing (RNA-seq) of 70 
9.5 day-old (E9.5) control and Setd5 mutant embryos. We detected 487 differentially 71 
expressed genes (DEGs) between Setd5+/+ and Setd5+/- mice (Fig. 1d and 72 
Supplementary Table 2), revealing an approximately equal number of up and down 73 
regulated genes. Gene ontology (GO) enrichment analysis, however, highlighted that 74 
genes upregulated in Setd5+/- embryos are associated with head and brain 75 
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development, while downregulated genes are involved in the formation of other 76 
embryonic parts including the neural crest, heart, limbs and skeleton (Fig. 1e, 77 
Supplementary Table 3). 78 
Among pathways disrupted by Setd5 haploinsufficiency  there is the Wnt 79 
signalling cascade (adjusted (adj.) p-value 2e-2, Supplementary Table 3). 80 
Accordingly, downregulated genes are enriched for β-catenin and transcription factor 81 
3 (TCF3) targets (adj. p-value: 1e-5 and 2e-10, respectively). Furthermore,  DEGs 82 
are enriched for genes previously associated with dysmorphic features observed in 83 
Setd5 mutant mice and patients6 (Fig. 1b-c; Supplementary Fig. 2d-e), for example 84 
genes linked to eye developmental defects such as microphthalmia (e.g. Otx2, 85 
Aldh1a3, Stra6 and Sox2, adj. p-value 4e-5).  86 
To substantiate our analysis and study how Setd5 haploinsufficiency affects 87 
gene expression in homogenous cell populations, we generated Setd5+/- mouse 88 
embryonic stem cells (ESCs) (Supplementary Fig. 3a) and differentiated them to 89 
embryoid bodies (EBs) and neural progenitor cells (NPCs) (Supplementary Fig. 3b). 90 
RNA-seq followed by differential expression analysis from Setd5+/+ and Setd5+/- 91 
(Supplementary Fig. 3c) ESCs, EBs and NPCs (Supplementary Table 2) indicated a 92 
significant overlap with the DEGs of the E9.5 embryos (67 genes; p-value: 6e-15, 93 
Supplementary Fig. 3d). GO-term analysis revealed that Setd5+/- ESCs and EBs 94 
display upregulation of genes related to epithelial and neuronal differentiation 95 
(Supplementary Fig. 3e, Supplementary Table 3) and downregulation of endoderm 96 
and mesoderm-related genes, indicating premature and excessive expression of 97 
neuroectodermal genes and suppression of genes associated with other germ 98 
layers. Similar to our findings in E9.5 embryos, downregulated DEGs in mutant EBs 99 
and NPCs are enriched for Wnt signalling (adj. p-value: 3e-5 and 6e-4, respectively) 100 
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and TCF3 targets (adj. p-value: 1.8e-7 and 8e-20, respectively). These results 101 
indicate that at early developmental stages Setd5 haploinsufficiency favours the 102 
expression of neuronal-related genes at the expense of other cell lineages, thus 103 
reflecting the abnormalities apparent in Setd5+/- mice. 104 
Setd5+/- mice exhibit overall normal brain morphology. 105 
In the central nervous system Setd5 is found throughout development and 106 
adulthood (Supplementary Fig. 4a-c), in multiple brain regions (Supplementary Fig. 107 
4c) and cell types, including inhibitory and excitatory neurons (Supplementary Fig. 108 
4d-e). Thus, we investigated whether haploinsufficiency of Setd5 affects brain 109 
morphology. Initially, we assessed NPC proliferation by 2-hour bromodeoxyuridine 110 
(BrdU) incorporation at embryonic day 12.5 (E12.5). In Setd5+/- embryos the number 111 
of BrdU labelled cells appears normal, indicating that NPC proliferation is not 112 
affected by Setd5 mutations (Supplementary Fig. 5a,d). Furthermore, Setd5+/- 113 
embryos present no alterations in cell survival, as indicated by the very low number 114 
of cleaved Caspase 3 positive cells (Supplementary Fig. 5b,e) and normal numbers 115 
of Pax6 and Tuj1 positive cells at E12.5 (Supplementary Fig. 5c,f). This data is in 116 
agreement with the observation that while the brain/body weight ratio is increased in 117 
Setd5+/- mice compared to Setd5+/+, the absolute brain size does not vary between 118 
the two genotypes. We also found no anomalies in brain morphology of Setd5+/- 119 
adult animals when assessed by Nissl staining (Supplementary Fig. 5g). Normal 120 
cortical lamination of Setd5+/- adult brain was confirmed in stainings for Cux1 and 121 
Ctip2 neurons. The whole cortex, individual layers, and the white matter in coronal 122 
brain sections displayed expected thicknesses (Supplementary Fig. 5h-i). In 123 
conclusion, Setd5+/- gross brain morphology is normal. 124 
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Setd5+/- mice show behavioural abnormalities, cognitive defects and enhanced 125 
long-term potentiation. 126 
Next, we investigated whether Setd5 haploinsufficiency affects mouse 127 
behaviour employing tests relevant for ASD- and ID-related mouse phenotypes12. 128 
Locomotion is not affected in Setd5+/- mice (Supplementary Fig 6a). Mutant mice 129 
also perform similarly to controls in tasks evaluating social interaction and social 130 
novelty, repetitive behaviours (i.e. marble burying and rotations in the open field) and 131 
anxiety (Supplementary Fig 6b-d), although Setd5+/- females show a slight reduction 132 
of anxiety-like behaviour in the elevated plus maze (Supplementary Fig 6d). 133 
Setd5+/- females, but not males, fail to build proper nests (Fig. 2a and 134 
Supplementary Fig. 6e), indicating deficient reproductive13 or maternal care 135 
abilities14. In addition, a delayed ontogenetic profile of ultrasonic vocalisation is 136 
apparent in Setd5+/- mouse pups, as they reach peak ultrasonic vocalisations 137 
approximately four days after their age- and sex-matched control littermates (Fig. 2b 138 
and Supplementary Fig. 6f), a delay comparable to deficits observed in ASD mouse 139 
models15. Because SETD5 patients display ID, we next assessed Setd5+/- mice with 140 
learning tasks. First, we examined behaviour of group-caged mice in the Intellicage, 141 
where animals get access to water by nose poking to doors located in front of bottles 142 
placed at the four corners of the cage. During learning trials, each mouse is 143 
randomly assigned to an “incorrect” corner, where nose poking would trigger an 144 
aversive air puff instead of access to water (Fig. 2c). On average, Setd5+/- mice 145 
perform more nose pokes per corner visit (Fig. 2c), even when they are not seeking 146 
for water (no licks) (Supplementary Fig.7a). As opposed to marble burying, in which 147 
digging16, but not stereotypic behaviour17 may play a role, nose poke repetitions 148 
represent a cleaner, higher order repetitive behaviour, previously reported in other 149 
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ASD mouse models18,19. Moreover, mutants perform fewer visits with nose pokes but 150 
without licks (Supplementary Fig. 7a), a behaviour previously linked to the 151 
hippocampus20. During the place avoidance trial, both Setd5+/+ and Setd5+/- animals 152 
visit the incorrect corner less frequently than any correct corner (Fig. 2c). After 153 
roughly 24h, Setd5+/+ animals learn the task, as they significantly reduce the number 154 
of nose pokes per visit in the incorrect corner. In contrast, Setd5+/- mice 155 
underperform, in that they continue to nose poke similarly frequent in both correct 156 
and incorrect corners (Fig. 2c-d), suggesting deficits in adaptive behaviour.  157 
Next, we assessed context fear memory acquisition and consolidation. Mutant 158 
and control mice are indistinguishable during acquisition of contextual fear, indicating 159 
similar sensory acuity (Supplementary Fig. 7b). However, one day after acquisition, 160 
when exposed to the context, female Setd5+/- mice freeze significantly more than 161 
their wild type littermates, denoting enhanced fear memory retention (Fig. 2e). This 162 
difference was not observed in males trained with the same strong protocol 163 
(Supplementary Fig. 7c) but it became obvious upon a slightly weaker training 164 
(Supplementary Fig. 7d). In all circumstances, both female and male Setd5+/- 165 
animals further fail to extinguish the repellent context-shock association and form a 166 
new, neutral memory, since they do not significantly diminish freezing when the 167 
context becomes safe (Fig. 2e and Supplementary Fig. 7c-d). Thus, the contextual 168 
fear conditioning (CFC) tests suggest that Setd5 haploinsufficiency is associated 169 
with a better memory retention but a worse capacity to extinguish memories, a 170 
feature already observed in mouse mutants for intellectual disability genes21. 171 
Although, Setd5+/- mice do not show increased anxiety-like behaviour, we 172 
substantiated our CFC analysis by performing the novel object location memory test, 173 
a hippocampus-dependent, aversive stimulus-independent, long-term memory test. 174 
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Mutant mice, when tested 24 h after receiving a subthreshold (3 minutes) training, 175 
show a significantly increased ability to discriminate between the old and new 176 
location (Fig. 2f, Supplementary Fig. 7e). However, this type of training typically 177 
produces no memory trace (defined as discrimination index > 30) in wild-type 178 
animals22, as is the case with our control littermates. 179 
To better understand the basis of the observed cognitive abnormalities, we 180 
tested long-term potentiation (LTP) of the synaptic transmission at the CA3-CA1 181 
synapses in hippocampal slices from Setd5+/- and Setd5+/+ littermates. In agreement 182 
with the observed increased memory retention, both early (Fig. 3a) and late (Fig. 3b 183 
and Supplementary Fig. 7f-g) LTP of local field potentials are enhanced in Setd5+/-. 184 
This phenotype, already observed in an ASD and ID mouse model23, suggests 185 
detrimental cellular and/or molecular synaptic plasticity mechanisms associated with 186 
abnormal learning and memory. 187 
Cognitive defects in Setd5+/- mice are accompanied by abnormal dynamics of 188 
postsynaptic gene expression. 189 
Because Setd5 is part of a histone modifier gene family we hypothesized that 190 
Setd5 loss of function mutations may prompt faulty regulation of gene expression 191 
during learning. Thus, we performed RNA-seq followed by differential expression 192 
analysis from hippocampal samples of naïve (homecage) and context fear 193 
conditioned mice (Supplementary Table 4).  194 
Compared to homecage, control samples obtained one hour after conditioning 195 
display a marked regulation of gene expression (280 DEGs FDR < 0.05, Fig. 4a, 196 
left). Among these genes we observed a significant upregulation of activity-197 
dependent immediate early genes, such as Fos and Egr224 (Fig. 4a, left), and 198 
enrichment for cAMP responsive element binding protein (CREB)-dependent genes 199 
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(adj. p-value 5.2e-5, Supplementary Fig. 8a, top). Three hours post-conditioning, 200 
however, in agreement with previous studies25, gene expression levels were mostly 201 
back to baseline and showed a pattern similar to homecage samples (63 DEGs, 202 
FDR < 0.05, Fig. 4a, left).  203 
Setd5+/- samples, while showing the expected upregulation of CREB-204 
dependent and activity–dependent immediate early genes one hour post-205 
conditioning (Fig. 4a, right and Supplementary Fig. 8a, bottom), differ markedly in 206 
their gene expression compared to samples obtained from control mice one hour 207 
and three hours post conditioning (180 and 212 DEGs respectively, FDR < 0.05). In 208 
contrast, Setd5+/- and control samples obtained from naïve homecage mice are 209 
virtually indistinguishable (4 DEGs, FDR < 0.05) indicating a dramatically different 210 
transcriptional response to training.  211 
Next, we clustered genes based on their transcriptional response at the 212 
different time points and compared their trajectories in mutant and control samples. 213 
While a number of genes, including early response genes, follow identical 214 
trajectories (Supplementary Fig. 8b, Supplementary Table 5) in the two genotypes, 215 
we identified 11 gene clusters displaying significantly different expression profiles 216 
between control and mutant animals (Fig. 4b, Supplementary Table 5). Thereafter, 217 
we performed in-silico analysis to identify biological pathways, cellular components 218 
and cell types potentially enriched in these clusters (Supplementary Table 6). Of 219 
note, the most significantly enriched set of genes belongs to the postsynaptic density 220 
(PSD) GO-term in cluster 6, consisting of genes displaying abnormally sustained 221 
expression three hours post-conditioning in Setd5+/- (Fig. 4b and Supplementary 222 
Table 6). Among the PSD protein encoding-genes belonging to this cluster, several, 223 
i.e. Shank1, CamKIIN1, CPEB1, FXR2P and Synaptopodin (Fig. 4c), have been 224 
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associated with memory retention, synaptic plasticity and ID26-30. Similarly, cluster 4 225 
is significantly enriched for genes encoding for proteins regulating synapse structure 226 
and activity, including SynGAP1, LRRC4 and p140Cap, which are also 227 
predominantly expressed in the PSD31-36 (Fig 4c). Finally, clusters 2, 5 and 7 (Fig. 228 
4b), comprising genes significantly affected in Setd5+/-, are enriched for histone H3 229 
acetylation, lysine-acetylated histone binding proteins and histone H4-R3 230 
methylation encoding genes, respectively (Supplementary Table 6), suggesting that 231 
the epigenetic response to CFC is partially affected in the mutants. Interestingly, the 232 
fine-tuning of histone H3 acetylation status has been previously associated with CFC 233 
dynamics and LTP of the CA3-CA1 hippocampus synapses22.  234 
SETD5 lacks methyltransferase activity and interacts with Hdac3 and Paf1 235 
complexes. 236 
Next, we investigated the molecular function of the SETD5 protein. Most SET 237 
domain-containing proteins are histone methyltransferases. Thus, we tested whether 238 
SETD5 exerts this enzymatic activity (Fig. 5a). Neither the SET domain (Fig. 5b) nor 239 
full-length SETD5 (Fig. 5c) showed methyltransferase activity in vitro. Likewise, 240 
histone H3 methylation status is comparable in control and Setd5+/- hippocampal 241 
samples (Supplementary Fig. 9a). Furthermore, neither in Setd5+/- ESCs nor in 242 
Setd5 null (Setd5-/-) ESCs (Supplementary Fig. 9b) are the histone methylation 243 
levels changed. These results are consistent with the fact that SETD5, like MLL5 244 
(KMT2E), does not have a canonical substrate-binding domain, which is conserved 245 
in the other active SET family proteins (Supplementary Fig. 9c). Thus, in agreement 246 
with previous reports9,37, we concluded that the SET domain of SETD5, similar to 247 
MLL5 (KMT2E)38 and the Drosophila SET protein UpSET39, lacks histone modifying 248 
enzymatic activity. 249 
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SETD5 might exert a function via interactions with other proteins. To address 250 
this point in a tractable system, and due to a lack of reliable Setd5 antibodies, we 251 
generated mouse ESCs expressing an endogenously tagged Setd5 (Setd5-HA-252 
FLAG) (Supplementary Fig. 9d-f). Immunoprecipitation coupled with quantitative 253 
mass spectrometry in ESCs and ESC-derived NPCs revealed that endogenous 254 
Setd5 is bound to two distinct protein complexes, Hdac3 and Paf1 (Fig. 5d,e, 255 
Supplementary Table 7 Supplementary Fig. 9g). The Hdac3 complex, containing 256 
Ncor1/2, Tbl1x/1xr1 and Hdac3 (Fig. 5e), regulates gene expression by modulating 257 
histone acetylation40,41, while the Paf1 complex, containing Paf1, Leo1, Cdc73, 258 
Wdr61 and Ctr9 (Fig. 5e), is associated with controlling RNA Polymerase II 259 
dependent transcription42.  260 
These results suggest that Setd5 acts with at least two different protein 261 
complexes in regulating chromatin environment and gene expression. Intriguingly, 262 
Tbl1x and Tblxr1 have been previously linked to the regulation of Wnt signalling43  a 263 
pathway appearing disrupted in Setd5 mutants. Furthermore, all the components of 264 
the HDAC3 complex (https://gene.sfari.org/database/human-gene/) and a part of the 265 
PAF1 complex (e.g., LEO1)44 (Supplementary Fig. 9h) have reported mutations 266 
associated with autism, suggesting a tight link between Setd5-associated protein 267 
complexes and neurodevelopment or brain function.  268 
SETD5 patient mutations disrupt SETD5-HDAC3/-PAF1 interaction. 269 
Several different SETD5 mutations have been reported in intellectually 270 
disabled individuals. If the interaction between SETD5 and its complexes plays a 271 
critical role in the brain, SETD5 mutations identified in patients (Supplementary Fig. 272 
10a) would lead to disruption of the interactions. To test this hypothesis, we first 273 
investigated the effect of six human SETD5 truncating mutations5,45-47 (Fig. 6a) on 274 
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SETD5 protein expression and cellular localization. Ectopic expression of the six 275 
human mutant proteins in HEK cells revealed that one mutant (R308*) lost protein 276 
expression and another (K399*) failed at nuclear localization, but four others (T552*, 277 
E720*, R1001* and S1258*) expressed nuclear proteins (Fig. 6b). We then selected 278 
two mutants (E720* and S1258*) displaying nuclear protein expression and tested 279 
whether they interact with the Hdac3 and Paf1 complex. To avoid a skewed result 280 
due to overexpression, we expressed the same dosage of the full length WT and 281 
each of the two truncating mutants (E720* and S1258*) (Fig. 6a) from the Rosa26 282 
locus in Setd5-/- ESCs (Supplementary Fig. 10b-d) and performed 283 
immunoprecipitation experiments. We found that only full-length wild type SETD5, 284 
but not the two truncated mutants, co-immunoprecipitated with Hdac3 and Tbl1x 285 
(Fig. 6c). These results imply that SETD5 is bound to the HDAC3 complex through 286 
its C-terminus (last 185 amino acids from 1258 to 1443) and that other mutations 287 
affecting these residues (e.g. T552* and R1001*) should result in loss of SETD5-288 
HDAC3 interaction. Similarly, mutations truncating the C-terminal domain of SETD5 289 
affect its interaction with Leo1, an ASD associated component of the Paf1 complex, 290 
although this interaction is only partially reduced (Fig. 6c). Altogether, these results  291 
highlight a potential role of SETD5 interacting chromatin proteins in the aetiology of 292 
the SETD5-associated disease.  293 
Setd5 haploinsufficiency increases histone acetylation without affecting Hdac3 294 
activity. 295 
Considering the interaction between Setd5 and Hdac3, we studied whether 296 
Setd5 affects histone acetylation levels. Immunoblot analysis of control and Setd5-/- 297 
ESCs (Supplementary Fig. 11a,b) shows that deletion of Setd5 results in increased 298 
histone H4 acetylation (Supplementary Fig. 11c). Likewise, the lysine 8 of histone 4 299 
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(H4K8) is more acetylated in hippocampal samples obtained from Setd5+/- mice than 300 
in controls (Supplementary Fig. 11d). Interestingly, H4K8 acetylation is also elevated 301 
three hours after CFC (Supplementary Fig. 11e) but is equivalent to control sample 302 
levels one hour post-conditioning (Supplementary Fig. 11f). Thus, H4K8 acetylation 303 
dynamics, observed after CFC training in wild type animals48, are altered upon 304 
heterozygous loss of Setd5 (Supplementary Fig. 11g). Despite the observed 305 
hyperacetylation, Hdac3 activity is not affected in Setd5+/- brain and ESC samples 306 
(Supplementary Fig. 11h,i), suggesting that the histone acetylation changes are 307 
independent of Hdac3 activity. They may thus be a consequence of other alterations 308 
in the chromatin environment for instance due to a defective interaction between 309 
Setd5 and the Paf1 complex.  310 
Setd5 occupies transcription start sites (TSS) with Hdac3 and Pol II.  311 
To elucidate the role of Setd5 in chromatin regulation, we examined the 312 
genomic distribution of Setd5 and its associated chromatin proteins (i.e., Hdac3 and 313 
Paf1 acting RNA polymerase II) in ESC using chromatin immunoprecipitation 314 
followed by DNA sequencing (ChIP-seq). Read counts for tagged Setd5 at annotated 315 
genes revealed that Setd5 is significantly enriched at TSS (defined as a 2.5 kb 316 
proximal region centred on the gene start sites) and predicted ESC-specific 317 
enhancers, but no other regions, such as transcription end sites (TES) and inactive 318 
enhancers (Fig. 7a). Hdac3 signals were also enriched in TSS and ESC enhancers 319 
(Supplementary Fig. 12a), and correlated with Setd5 signals (Fig. 7b). RNA 320 
polymerase II (Pol II) ChIP-seq signals, detected with an antibody recognizing both 321 
Pol II recruited into the preinitiation complex (non-phosphorylated) and initiated Pol II 322 
(phosphorylated at serine 5), showed significant enrichment at TSS (Supplementary 323 
Fig. 12 b). Notably, the most pronounced signals of Setd5 were observed at TSS 324 
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occupied by both Hdac3 and Pol II (Fig. 7b), implying that our immunoprecipitation 325 
coupled with mass spectrometry result captured the Setd5-associated complexes at 326 
TSS.  327 
Setd5 regulates Pol II occupancy at transcriptional start sites of 328 
neurodevelopmental genes.  329 
To clarify SETD5’s role at the TSS, we investigated whether Setd5 is required 330 
for Hdac3 or Pol II (via Paf1) recruitment. We analysed the genome-wide localization 331 
of Hdac3 and Pol II in control and Setd5 mutant (i.e. Setd5+/- and Setd5-/-) ESCs (Fig. 332 
7c). We also examined the genomic distribution of acetylated histone H4 (pan-333 
acetylated H4) and H3 (acetylated H3K27) as a potential outcome of Hdac3 activity. 334 
Global analysis revealed that Hdac3 occupies numerous promoters and enhancers 335 
across control and Setd5 mutant ESCs (Supplementary Fig. 12a), with minimal 336 
changes between genotypes (21 differential peaks in Setd5+/+ vs. Setd5+/-, 34 337 
differential peaks in Setd5+/+ vs. Setd5-/-, FDR < 0.05, Supplementary Fig. 12d). Our 338 
results suggest that Setd5 is not involved in Hdac3 recruitment to the chromatin, as 339 
opposed to previous hypotheses9.  340 
Interestingly, Pol II ChIP-seq profiles showed a broad redistribution in Setd5+/- 341 
and Setd5-/- cells. The ratio of promoter proximal to gene body Pol II density (i.e. 342 
pausing index) is decreased in 44% of genes (n=4144) and increased in 26% of 343 
genes (n=2487) containing Pol II at the TSS, in both Setd5+/- and Setd5-/- versus 344 
Setd5+/+ ESCs (Fig. 7d). Moreover, when comparing Setd5+/- cells to controls, we 345 
observed significantly increased Pol II occupancy at 559 TSS (Fig. 7c,e and 346 
Supplementary Fig. 12e) and decreased occupancy at 182 TSS (Supplementary Fig. 347 
12e,g, Supplementary Table 8). Setd5-/-  cells also showed similar Pol II changes at 348 
those TSS (593 differential peaks in wild type vs. Setd5-/-, FDR < 0.05, 349 
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Supplementary Fig. 12e). The TSS with increased Pol II are enriched for Hdac3 and 350 
depleted for both H3K27ac and H4ac signals over the inputs (Fig. 7e) implying a 351 
poised transcriptional state of these genes. Global distribution of H3K27 acetylation 352 
was unchanged in Setd5-/- ESCs at TSS as well as enhancers (Supplementary Fig. 353 
12c,f), consistent with minimal changes in Hdac3. In agreement with the 354 
immunoblots (Supplementary Fig. 11c), average ChIP-seq profiles of acetylated H4 355 
(pan-acetylated H4) revealed significantly increased acetylation at gene bodies in 356 
Setd5 mutant cells (Supplementary Fig. 12h), which might be linked to changes of 357 
Pol II rather than Hdac3 activity. All together, these results suggest that Setd5, 358 
through its interaction with chromatin-associated proteins (e.g. Paf1) functions to 359 
maintain proper levels of Pol II at TSS and gene bodies. 360 
Next, we investigated whether chromatin alterations driven by Setd5 361 
haploinsufficiency are associated with changes in gene expression. We found that 362 
DEGs in Setd5+/- cells are enriched for genes showing both Hdac3 and Pol II signals, 363 
but no H3K27ac, at the TSS (adj. p-value: E9.5: 8.3e-22; ESCs: 4e-2; EBs: 1.6e-13; 364 
NPCs: 1.9e-14). This result suggests that TSS of DEGs show a poised chromatin 365 
state in ESC, implying that poised genes may be more susceptible to Setd5 366 
haploinsufficiency. Thus, we extended our analysis to the 559 genes featuring 367 
increased Pol II at the TSS in Setd5+/- ESCs and poised chromatin state (enriched for 368 
Hdac3 and depleted for both H3K27ac and H4ac signals), thereby also capturing 369 
genes possibly not expressed in control ESCs. GO term analysis of these genes 370 
revealed neuronal development and neuronal signalling pathways (Fig. 7f, 371 
Supplementary Table 8). Furthermore, genes showing a Setd5 dosage dependent 372 
Pol II increase at the TSS (i.e. higher fold change in Pol II occupancy in Setd5-/- 373 
compared to Setd5+/- mutant cells) are significantly enriched for Wnt signalling-374 
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related genes (adj. p-value: 8e-3), consistent with our differential expression 375 
analysis. In contrast, genes with decreased Pol II at the TSS were not enriched for 376 
any specific GO-term.  377 
Finally, we examined the expression level of the 559 genes showing 378 
increased Pol II at the TSS. Average read counts were low in these genes, 379 
consistent with the low levels of H3K27ac and H4ac (Fig. 7e), indicating that in 380 
control conditions these genes are mostly not expressed in ESCs. Nevertheless, a 381 
subset (~20%, 124 genes) of the genes show increased expression in Setd5+/- ESCs 382 
(Fig. 7g,h, Supplementary Table 8), suggesting that these genes are more prone to 383 
transcription in Setd5 haploinsufficiency in response to increased Pol II at TSS.  384 
Collectively, these results indicate that Setd5 maintains proper Pol II levels at 385 
numerous TSS, most likely via its interaction with the Paf1 complex. When Setd5 386 
expression is reduced in ESCs, Pol II is globally redistributed and simultaneously 387 
increasingly positioned at the TSS of multiple neuronal-specific genes, possibly 388 
priming them for transcription. While Setd5 is not involved in global Hdac3 389 
recruitment, our data suggests that Setd5 exerts its regulatory function preferentially 390 
at Hdac3 occupied TSS through Paf1-mediated Pol II recruitment and pausing.  391 
 392 
Discussion 393 
Mutations in SETD5 are emerging as a relative frequent cause of ID and ASD, 394 
however the pathophysiological underpinnings remain uncovered.  395 
We employed in vivo and in vitro mouse models to study how Setd5 396 
haploinsufficiency affects development and cognition. Our data suggest that during 397 
early development Setd5 is critical in preventing expression of neuronal genes and 398 
maintaining correct levels of non-neuronal gene transcripts and cell types. Thus, the 399 
  17
variability of the clinical features of patients carrying different SETD5 mutations and 400 
the phenotypic variability of Setd5+/- mice may reflect dosage-dependent effects on 401 
regulation of gene expression and/or stochastic variations in cell-fate determination 402 
early in development. Dosage dependent effects and changes in cell-fate 403 
determination were already suggested by previous studies, which analysed some 404 
effects of homozygous and transient reduction of Setd5 in non-neuronal tissues9,37. 405 
Thus, our study, while focusing on the disease-relevant haploinsufficient model, 406 
supports some of the previous conclusions.  407 
Most importantly, while Setd5+/- mice do not have obvious brain architecture 408 
abnormalities, our data show for the first time that Setd5 haploinsufficiency leads to 409 
behavioural abnormalities and impairs the optimized transcription program 410 
associated with learning and memory. Interestingly, Setd5 haploinsufficiency is 411 
associated with abnormal response of PSD gene expression. Thus, future studies 412 
analysing synaptic plasticity in Setd5 mutants are warranted. 413 
Our findings implicate Setd5 in the regulation of gene transcription through its 414 
interaction with the Hdac3 and Paf1 complexes. While we extend the observation of 415 
this interaction to neural precursors, this complex was ascertained in mouse ESC 416 
and HEK 293 cells9, implying that SETD5-HDAC3-PAF1 interaction is conserved 417 
across different species and cell types. Interestingly, Hdac3 has been shown to act 418 
as a negative regulator of hippocampal long-term memory22 and HDAC3 inhibitors 419 
described as memory enhancers. Similar to the Setd5+/- phenotype revealed here, 420 
focal deletion of Hdac3 in the mouse dorsal hippocampus augmented novel object 421 
location memory22, fear memory retention, and long-term potentiation49. However, 422 
the extinction of fear memory, which is substantially affected in the Setd5+/- animals, 423 
has not been examined in relation to Hdac3 deficiency. This behavioural inflexibility 424 
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of Setd5 mutants points to the possibility that chronic abnormal regulation of the 425 
HDAC3 complex may lead to impairment of cognition rather than its enhancement. In 426 
agreement, conditional homozygous Hdac3 knockout in forebrain excitatory neurons 427 
was associated with impaired spatial learning50, and our Setd5 mutants present with 428 
learning inefficiency and/or impaired adaptive learning. Furthermore, Setd5 interacts 429 
with the Paf1 complex, which is also associated with ASD.  430 
In summary, our results are consistent with a model in which Setd5 regulates 431 
Pol II occupancy at TSS of neuronal-related genes via its interaction with the Hdac3 432 
and Paf1 complexes. Whether Setd5 interacts with Hdac3 and Pol II simultaneously 433 
remains to be determined and warrants a structural study of Setd5 within its protein 434 
complexes. In addition, while providing evidences that Setd5 regulates gene 435 
transcription through its interaction with Hdac3 and Paf1 complexes, it remains 436 
unclear whether anomalies in these interactions underlie all of the mutants’ 437 
phenotypes. In fact, although our data dismiss methyltransferase activity of SETD5, 438 
there remains the possibility that Setd5, potentially through interaction with other 439 
proteins, contributes to brain development and function also in other ways.  440 
Our study, comprehensively combining molecular, circuit and behavioral 441 
analyses, is the first to analyse the consequences of Setd5 haploinsufficiency in 442 
neural cells, brain and behaviour, advancing the understanding of the function of 443 
epigenetic factors for development, learning and cognition. Furthermore, our data 444 
indicate that SETD5 mutations affect a biological pathway that is dysfunctional in 445 
other ID and ASD cases, implying that this work is relevant for a number of related 446 
disorders. 447 
 448 
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Mouse RNA-seq data are deposited at GEO with accession number GSE119498. 450 
RNA-seq and ChIP-seq data from in vitro samples is deposited at ENA under the 451 
following accession numbers: PRJEB28477, PRJEB28476, PRJEB28475, 452 
PRJEB28474, PRJEB28473 and PRJEB28472. 453 
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Figure Legends 650 
Fig. 1. Early developmental defects and altered gene expression at E9.5 in 651 
Setd5+/- mice. a, Representative images of brain and body from >P30 Setd5+/+ and 652 
Setd5+/- females indicating similar brain size, but abnormally small body in the 653 
mutant (left). Quantitative comparison of the normalised brain/body weight and 654 
kidney/body weight ratios in P1 pups (n=15) and adult females (n=12, bar graphs on 655 
the right) (values normalised to Setd5+/+), *P<0.05 (two-tailed Mann Whitney U test), 656 
***P<0.001 (one-way ANOVA/two-tailed t test), n.s. not significant; data presented as 657 
means and SEM, as well as scatter plot (exact P values and detailed statistics 658 
provided in Supplementary Table 1; also refer to Supplementary Fig. 2c). b, 659 
Representative picture of the white belly spot observed in 31% of Setd5+/- animals as 660 
compared to only 2% in Setd5+/+ animals (total n is 222 Setd5+/+ and 157 Setd5+/-, 661 
both females and males were included). c, Characteristic photographs of Setd5+/-  662 
eye abnormalities found in 15% of Setd5+/-  animals (bottom picture: from our own 663 
cohort; top picture: taken with permission from the International Mouse Phenotyping 664 
Consortium http://www.mousephenotype.org/data/genes/MGI:1920145); doughnut 665 
charts show observations made in our own cohorts (total n is 222 Setd5+/+  and 157 666 
Setd5+/-); eye abnormalities in Setd5+/- mice include corectopia, mydriasis and 667 
microphthalmia; d,  Volcano plot for differential expression analysis of genes in 668 
embryonic day (E) 9.5 Setd5+/- mouse embryo samples (n=3 embryos per genotype). 669 
Y-axis: negative decimal logarithm of adj. P value; X-axis: binary logarithm of fold 670 
change; colour code: genes significantly (sign.) (FDR<0.05, EdgeR, likelihood ratio 671 
test) down- (blue) and upregulated (red) in Setd5+/- embryos; not significant 672 
expression changes (grey); e, Selected biological processes (GO) enriched in 673 
differentially expressed genes (DEGs) in E9.5 animals; Inner circle: score for 674 
enrichment of either upregulated (red) or downregulated DEGs (blue). Numbers 675 
show maximum enrichment scores and gridlines indicate maximum and half 676 
maximum values. Colour intensity scales with p-value. Outer circle: log2(fold 677 
change) (y-axis) for up- and downregulated DEGs per term. Scale is indicated at the 678 
top of the plot, gridlines divide plot into four equal parts, grey line represents zero. 679 
 680 
Fig. 2. Behavioural abnormalities and cognitive defects as consequence of 681 
Setd5 haploinsufficiency in mice. a, Representative images of the nests built by 682 
controls and mutants (left) and nest scores (right) showing impaired nesting abilities 683 
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in Setd5+/- females (n=10 animals per genotype, *P<0.05, two-tailed Mann-Whitney U 684 
test). b, Isolation-induced ultrasonic vocalization profiles of Setd5+/+ (grey) and 685 
Setd5+/- (red) female mouse pups displaying delayed peaking in the mutants (n=21 686 
P2, 19 P4, 19 P6, 18 P8, 18 P10, 17 P12 female mouse pups per genotype, 687 
*P>0.05, **P>0.01, one-way ANOVA/two-tailed t test or Mann-Whitney U test – 688 
detailed statistics presented in Supplementary Table 1). c-d,  Place avoidance task 689 
in the Intellicage: cartoon showing that nose poking in the correct corner allows 690 
access to water (green), while incorrect nose pokes (red corner) trigger an aversive 691 
air puff (black) (c, left); the two genotypes (n=14 females per genotype in both c and 692 
d) visit incorrect and correct corners similarly during the 48h long trial (c, middle), but 693 
Setd5+/- make more nose pokes per visit (c, right), at both correct and incorrect 694 
corners; the bar graph (c, right) and the kinetics of nose pokes/visit ratio (d) indicate 695 
that Setd5+/+ females learn the task after 24h and nose poke significantly less at the 696 
incorrect corner during the second peak of activity, while the Setd5+/- females 697 
continue to nose poke similarly often (d); peaks of the fitted curves in d have 698 
amplitudes (mean and SEM) of 7.25 ± 0.62 nose pokes per incorrect corner (control, 699 
grey) and 8.72 ± 0.83 (mutant, red), during the first 24h (learning phase), and of 4.63 700 
± 0.39 (control) and 8.75 ± 0.7 (mutant) during the last 24h (test phase). e, 701 
Contextual fear-conditioned memory retention and extinction scored as percent 702 
freezing during a 3-min exposure to the context, n=18 female mice per genotype; f, 703 
Subthreshold training (3 min) in novel object location memory test induces abnormal 704 
memory retention in mutants (n=13 females per genotype). ***P<0.001, **P<0.01, 705 
*P<0.05, n.s., not significant; data presented either as means and SEM, or as 706 
medians, as well as scatter plot. For detailed statistics, please refer to 707 
Supplementary Table 1. 708 
 709 
Fig. 3. Increased LTP in Setd5+/- mice. a, Comparison of the post-tetanic 710 
potentiation and early-LTP (end of first hour after induction) of the CA3-CA1 711 
synapses in the stratum radiatum of acute dorsal hippocampal slices obtained from 712 
n=10 male mice (P21-P24) of either genotype; one slice per mouse; stimuli were 713 
applied every 30s and results are means ± SEM for all mice; a stable baseline was 714 
recorded for 30-60 min (shown here – 10 min) and LTP was induced at time 0 715 
(arrow) by high frequency stimulation (HFS, 4 x 100 stimuli of 0.2 ms at 100 Hz, 716 
every 5s). Right panel shows representative traces of fEPSPs obtained at baseline 717 
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(top), 1h after HFS (middle, early-LTP) and 5h after HFS (bottom, late-LTP) from 718 
either genotype (also refer to Supplementary Fig. 7f containing the means ± SEM 719 
for entire recordings). b, Quantifications of the percent potentiation at various 720 
moments after LTP induction, in dorsal hippocampal slices from control and mutant 721 
animals, showing elevated early LTP (1h, n=10) and late LTP (3h n=10, 4h n=8, 5h 722 
n=6) in Setd5+/- mice; *P<0.05. Boxplots indicate medians (middle line), 25%-75% 723 
interquartile range (box) and minimum and maximum data point (whiskers). For 724 
detailed statistics, please refer to Supplementary Table 1. 725 
 726 
Fig. 4. Gene expression dynamics are altered in the Setd5+/- hippocampus after 727 
CFC training. a, Volcano plots displaying gene expression changes 1h or 3h after 728 
conditioning in wild type (n=4 animals) and mutant (n=5 animals): 280, 229, 169 and 729 
273 significant DEGs, respectively (FDR <=0.05, EdgeR, likelihood ratio test). The y-730 
axis shows the negative decimal logarithm of the adjusted P value and the binary 731 
logarithm of the fold change is shown on the x-axis; blue/red, genes down- and 732 
upregulated at the later time point, respectively; green, differentially expressed 733 
immediate-early genes (see reference 22); grey, not significant. b, Genes with 734 
significantly different responses (n=286) to the CFC clustered by their expression 735 
trajectories. Top row (left to right): 15, 43, 18 and 23 genes, middle row: 44, 24, 33 736 
and 21 genes, bottom row: 37, 16 and 12 genes, respectively. Thick lines, average 737 
of all genes per cluster; thin lines, single genes; grey, Setd5+/+; red, Setd5+/-; 738 
homecage (HC), n=5; 1h, n=4; 3h, n=5 animals per genotype; c, Schematic 739 
illustration of a synapse highlighting post-synaptic genes exhibiting different 740 
responses in Setd5+/- animals upon CFC. Colouring indicates association of genes to 741 
clusters in b. 742 
 743 
Fig. 5. SETD5 lacks methyltransferase activity and interacts with PAF1 and 744 
HDAC3 protein complexes. a, Schematic representation of the SET domain 745 
methylation assay. The GST-tagged SET domain of SETD5 is incubated with a 3H-746 
labeled S-Adenosyl methionine (SAM) substrate and mono- or oligonucleosomes 747 
purified from HeLa cells, followed by SDS-PAGE. The methylation activity signal is 748 
detected by autoradiography. b, Methylation assay results for the GST-tagged SET 749 
domain. Left: radioactive films for the SET domain; Right: PRC2 complex used as a 750 
positive control for the assay. Arrowheads indicate background levels of histone H3 751 
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methylation caused by contaminants bound to nucleosomes (Nuc.). The experiment 752 
was repeated three times with similar results. c, Methylation assay results for full 753 
length FLAG-tagged SETD5 overexpressed in HEK293T cells. Left: radioactive film 754 
results; Right: coomassie staining of SDS-PAGE; Bottom-right: Western blot of 755 
immunoprecipitated FLAG-tagged SETD5. Arrowheads indicate FLAG-beads 756 
immunoglobulins (Ig); b, FLAG-beads; the experiment was performed once. Refer to 757 
Supplementary Fig. 14 for full scans of films, blots and gel in b-c; d, Correlation 758 
plot of the Setd5 interacting proteins in ESCs (x-axis) and NPCs (y-axis) identified by 759 
quantitative TMT mass spectrometry. Immunoprecipitation samples of the 760 
endogenously tagged Setd5-HA are compared with non-tagged wild type samples. 761 
Colour code: proteins significantly enriched in both ESCs and NPCs (red); significant 762 
only in ESCs (yellow) or in NPCs (purple); not significant (grey). Adjusted P value < 763 
0.05 and log2 (Fold Change) > 0, limma statistical analysis; n=2 biologically 764 
independent samples. e, Interaction network of proteins found to significantly interact 765 
with Setd5 both in ESCs and NPCs from both TMT and label free mass 766 
spectrometry. Black edge thickness indicates interaction confidence from data 767 
generated in this study. Thin edge colour indicates String interaction score (blue, 768 
low; red, high). Orange, Setd5 bait; blue, Hdac3-Ncor-Tbl1x complex; green, Paf1 769 
complex; grey, other proteins significantly interacting with Setd5. 770 
 771 
Fig. 6. SETD5 patient mutations disrupt SETD5-HDAC3/-PAF1 interactions. a, 772 
Schematics of SETD5 rescue constructs representing selected human patient 773 
mutations. Open reading frame carrying the disease-associated truncating mutations 774 
or the endogenous stop codon is fused in frame with a P2A sequence and a GFP 775 
reporter. All constructs carry a N-terminal FLAG-HA tag. b, Western blot of wild type 776 
(WT) and truncated mutant SETD5 proteins overexpressed in HEK cells. Replicate 777 
lanes come from two independent cell transfections; samples were separated into 778 
cytoplasmic and nuclear fractions. Neg., empty vector; black arrows indicate 779 
expected bands for each construct. The experiment was repeated twice with similar 780 
results. c, Western blots of FLAG immunoprecipitation of SETD5 WT, SETD5 1258*, 781 
and SETD5 E720* in Setd5-/- ESC rescue lines. The nuclear protein Oct4 served as 782 
negative control. IN, input: nuclear extract before immunoprecipitation. FT, flow 783 
through, unbound to beads; IP, immunoprecipitation eluate with triple-FLAG peptide; 784 
1% of IN and FT and 50% of IP eluate were loaded. The experiment was repeated 785 
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three times with similar results. All immunoblots shown are cropped; see 786 
Supplementary Fig. 14 for full-length blots in b-c. 787 
 788 
Fig. 7. Setd5 haploinsufficiency in ESCs results in increased Pol II occupancy 789 
at the TSS of a subset of neurodevelopmental genes. a, Boxplots of ChIP-seq 790 
signal for 5 different genomic features: transcription start sites (TSS) bound (Pol II 791 
TSS, n=16342) or not bound (Inactive TSS, n=17817) by RNA-Pol II, transcription 792 
end sites (TES, n=34159), intergenic ESCs specific enhancers (n=4099), and other 793 
tissue intergenic enhancers (n=43657). Setd5 ChIP-seq was performed using 794 
endogenously tagged (Setd5-HA) compared to non-tagged (Setd5+/+) ESCs for 795 
antibody background. One-sided Mann–Whitney U test; p-values are in the figure. b, 796 
Boxplots of Setd5 ChIP-seq signal at 4 genomic regions: TSS with either or both 797 
Hdac3 and Pol II (+Hdac3 +Pol II, n=13314; +Hdac3 –Pol II, n=701; –Hdac3 +Pol II, 798 
n=2890), and intergenic ESCs specific enhancers with Hdac3 peaks (+Hdac3 ESCs 799 
Enhancer, n=688); one-sided Mann–Whitney U test. c, Representative ChIP-seq 800 
tracks of Setd5-HA and Pol II in Setd5+/HA and Setd5 mutant ESCs at the Meis2 gene 801 
locus. Signals are input-subtracted, merged replicates Reads per Genomic Content 802 
(RPGC); Refer also to Supplementary Fig. 14 for complete tracks; experiments 803 
performed with two independent clonal lines with similar results. d, Density plot of 804 
genes with reduced (upper panel, n=4144) or increase (lower panel, n=2487) Pol II 805 
pausing index in both Setd5+/- and Setd5-/- ; X-axis is in log10 scale; one-sided 806 
Kolmogorov–Smirnov test, as compared to Setd5+/+. e, Boxplots showing Setd5-HA, 807 
Pol II, Hdac3, H3K27ac and H4 pan acetylation ChIP-seq signals in Setd5+/HA and 808 
Setd5 mutants with significantly increased Pol II occupancy at TSS in Setd5+/- (FDR 809 
< 0.05, EdgeR statistical analysis, Supplementary Fig. 12e), n=559 genes. f, Gene 810 
ontology enrichment analysis for genes presented in (e); GOstats statistical analysis. 811 
g, Boxplot showing RNA-seq counts for a subset of genes with increased Pol II at 812 
the TSS. Genes in (e) were clustered (k-means) and a cluster (n=124 genes) with 813 
more reads in Setd5+/- ESCs was presented. Setd5+/+ and CRISPR/Cas9 clonal 814 
control lines (Setd5+/+; tr.) were merged. One-sided Mann–Whitney U test; Y-axis in 815 
log10 scale. h, Heatmap of 35 representative genes used in (g). Boxplots in a, b and 816 
e represent means of 2 biological replicates from two independent clonal lines, 817 
normalized by input RPKM values (dashed horizontal line represents input baseline). 818 
Data points, less than 5 or more than 95 percentile of mean RPKM, were removed in 819 
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a, b, and e. All data points are presented in g. The upper, centre, and lower line of 820 
the boxplot indicates 75%, 50%, and 25% quantile, respectively. Whiskers extend to 821 
the most extreme datapoint within 1.5-times the interquartile range. Outliers are not 822 
shown. 823 
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 867 
 868 
 869 
METHODS 870 
Ethical approval 871 
All animal protocols complied with directive 2010/63/EU of the European Parliament 872 
and Council, the 3R (reduce, replace, refine) principle (Russel and Burch) and were 873 
approved by the Institutional Animal Care and Use and Ethical Committee at IST 874 
Austria.  875 
 876 
Mice 877 
Setd5tm1a(EUCOMM)Wtsi (International Mouse Phenotyping Consortium) were mated with 878 
homozygous Flip mice (Jackson Laboratories) to remove the NeoStop cassette. The 879 
resultant heterozygous Setd5+/fl females (Supplementary Fig. 1a) were crossed with 880 
CMVCre (B6.C-Tg(CMV-cre)1Cgn/J) males to obtain Setd5+/- mice (Supplementary 881 
Fig. 1a). Setd5+/- mice were backcrossed to the N10 generation in C57BL/6J mice 882 
and used for our experiments. The Setd5GFP mouse has been described elsewhere51 883 
and was kindly provided by Prof M.A. Magnuson. Animals were housed in groups of 884 
3-4 animals per cage and kept on a 12 h light/dark cycle (lights on at 7:00 am), with 885 
food and water available ad libitum, unless otherwise specified.   886 
 887 
Generation of Setd5 knock in and knock out cell lines  888 
The Setd5 knock in cell line was created by adapting a published method52. A donor 889 
plasmid was generated from the pFETCh_Donor plasmid (addgene ID #63934). We 890 
exchanged the Neomycin/Kanamycin resistance with Emerald GFP, introduced an 891 
HA tag upstream of the triple FLAG tag, and cloned 1Kb of Setd5 homology arms 892 
upstream and downstream of the construct. ESCs were electroporated with a 893 
CRISPR/Cas9 plasmid targeting the unique transcription end site of Setd5 together 894 
with the modified pFETCH_Donor plasmid. To increase homologous-directed 895 
recombination efficacy, cells were treated with 10 µM of SCR7 (Xcessbio 896 
Biosciences) for 24h before the electroporation. Successfully electroporated cells 897 
were selected by single cell fluorescence-activated cell sorting (FACS) for GFP 898 
positive events. Correct insertion was confirmed by genotyping PCR and protein 899 
expression was tested using western blot (WB).   900 
Setd5 knock out cell lines were generated using CRISPR/Cas9. For the generation 901 
of heterozygous Setd5 line 1kb homology arms matching intron 2 and intron 15 of 902 
the Setd5 locus were cloned inside the HR110PA-1 plasmid (System Biosciences) 903 
carrying a red fluorescent protein (RFP) and puromycin resistance cassette (PuroR). 904 
ESCs were electroporated with two CRISPR/Cas9 plasmids (pSpCas9(BB)-2A-GFP 905 
(PX458), addgene ID #48138) targeting intron 2 and intron 15 of Setd5 and the 906 
HR100PA-1 donor plasmid carrying the RFP/PuroR cassette. Positive clones were 907 
selected by 1µg/ml puromycin treatment for 1 week. Validation of the positive 908 
cassette insertion in the Setd5 locus was carried out by genotyping PCR. Biological 909 
replicates come from different clones. 910 
The generation of ∆SET Setd5 heterozygous or homozygous cell lines was 911 
performed by transfecting ESCs with two CRISPR/Cas9 plasmids with guides 912 
targeting intronic regions 20-to-70bp upstream of exon 7 or downstream of exon 8. 913 
Single cells were FACS sorted and the resulting clones were genotyped by PCR. 914 
Biological replicates are different clonal lines carrying the same mutation. CRISPR 915 
control lines are single cell-derived clones that were not edited in the targeted site or 916 
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in the top 10 potential off target sites. CRISPR/Cas9 guides were designed using 917 
Optimized CRISPR Design tool (http://crispr.mit.edu/). We choose guides with 918 
predicted off target sites in intergenic regions. For each guide we selected the top 10 919 
off target sites and designed PCR primers spanning 300bp upstream and 920 
downstream from the predicted sites. PCR bands were resolved on 1% agarose gel. 921 
None of the guides showed a band shift in the clonal lines compared to wild type 922 
(WT) controls (data not shown). To check for small DNA indels the bands were cut 923 
out from the gel and sent for Sanger sequencing. Sequences were aligned against 924 
the reference mouse genome and no guide showed signs of off target activity in the 925 
predicted site. 926 
 927 
Methylation assay 928 
The human GST-tagged SET domain of SETD5 (E200-E566) was purified from 929 
BL21(DE3) E.Coli. For each reaction 2 µg of recombinant SET or 2 µg of 930 
recombinant PRC2 complex (Active Motif #31387) were incubated with 10 μg of 931 
HeLa cells purified mononucleosomes or 2 µg of di/tri- or oligonucleosomes together 932 
with 5 µCi of 3H-S-Adenosylmethionine. The final reaction volume was brought to 30 933 
µL with methylation assay buffer (20 mM Tris-HCl pH 8, 10% Glycerol, 5 mM Mg2Cl, 934 
60 mM KCl, and 2 mM DTT). Samples were incubated for 2h at 30°C. The reaction 935 
was blocked by adding SDS-loading buffer and boiling the samples at 95°C for 10 936 
minutes. The remaining 3H-S-Adenosylmethionine was separated from the rest of 937 
the proteins by SDS-PAGE. Coomassie stained gels were incubated with Amersham 938 
Amplify Fluorographic Reagent (GE NAMP100V) for 30 minutes followed by gel 939 
dehydration for 2h at 60°C. Radioactive signal was detected by exposing the gel to 940 
autoradiography film from 4h up to 1 month at -80°C. 941 
 942 
Messenger RNA-sequencing (mRNA-seq) 943 
ESC, EB and NPC mRNA extraction was performed as described in the 944 
Supplementary note. RNA extracts that passed quality control were used for library 945 
preparation. Libraries were prepared using the oligo-dT capture kit (NEB) and 946 
sequenced on Illumina HiSeq 2000 at EMBL, Heidelberg Genomics Core facility. 947 
Fastq files that passed quality control were aligned to the mm10 reference genome 948 
using bowtie2 v0.353, the generated bam files were used for counting reads using the 949 
HTseq tool v0.6.154. Coherence between samples, time points and replicates was 950 
verified by principal component analysis (PCA). Differential expression analysis was 951 
performed using the R package DESeq2 v1.1655. Gene Ontology enrichment 952 
analysis was done using the Bioconductor package GOstats version 2.46.056.  953 
Mouse tissues for mRNAseq were rapidly dissected on ice and snap frozen in liquid 954 
nitrogen. For embryonic day (E) 9.5 embryos genotyping was carried out on 955 
placental tissues. Whole embryos or the left hippocampal CA region were used for 956 
RNA extraction and library preparation.  957 
Sequenced libraries raw reads were trimmed before alignment to mm10 reference 958 
genome using STAR version 2.5.457. Read counts per gene were derived using 959 
STAR (Option -quantMode GeneCounts). Coherence of biological replicates was 960 
assessed using PCA, and sample distance clustering; one sample (WT, 1h) was 961 
excluded due to its clustering away from all other samples. Differential expression 962 
analysis of CA and mouse embryos was performed employing RUVSeq as 963 
described58 and EdgeR v3.22.259 including the RUV variables in the design. Genes 964 
with FDR<=0.05 were deemed significantly differentially expressed. Averaged log 965 
transformed CPM values were normalized by calculating gene-wise z-scores. K-966 
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means clustering was performed using Pearson correlation as distance measure and 967 
selecting a suitable cluster number (k=11) with minimal Davies Bouldin index and a 968 
minimum cluster size above 10 genes. To identify clusters with similar trajectories 969 
between genotypes, genes differentially expressed in at least one comparison were 970 
clustered in the same way (k=22). Gene Ontology enrichment analysis was done 971 
using GOstats v2.46.056 with a P value cut off of 0.001 and conditional testing 972 
enabled. For the E9.5 data random sampling was used to exclude terms enriched in 973 
random gene sets to control for enrichment in overall expressed genes. E9.5 mouse 974 
embryos GO enrichment results were visualized using a custom script and the 975 
GOplot package (1.0.2)60. Overlap between E9.5 data and in vitro datasets was 976 
visualized using a customized script based on the circlize package (0.4.4)61. 977 
Enrichment for cell type specific expression was performed using the EWCE tool 978 
(0.99.2)62 using the scRNA-seq data from Zeisel et al63. Enrichment analysis for 979 
disease genes (OMIM), transcription factor targets as well as pathway related genes 980 
was done via the Enrichr web tool64,65. Other enrichment analyses were all done 981 
using a one-sided Fisher test in R. Hdac3 target genes for comparison with CA data 982 
were derived from published ChIP-seq data from mouse hippocampus66, E9.5 data 983 
was compared to ChIP-seq data generated in this study. Refer to the Supplementary 984 
note for more details. 985 
 986 
Setd5 immunoprecipitation (IP) followed by liquid chromatography-mass 987 
spectrometry (LC-MS) 988 
For the IP of endogenously tagged Setd5 we used ESCs and NPCs. Briefly, 200 989 
million cells were harvested and snap frozen in liquid nitrogen. Cells were lysed as 990 
described67. Nuclear enriched pellets were resuspended in a 420 mM salt buffer, 991 
incubated 15 min at 4°C and spun down to remove insoluble material. The soluble 992 
fraction was diluted to 150 mM salt concentration. Nuclear enriched samples were 993 
incubated with 15 µL of anti-FLAG M2 beads (Sigma Aldrich) overnight at 4°C. After 994 
the incubation, beads were washed 3 times with a 300 mM wash buffer, followed by 995 
a two-times 1h elution with 40 µL of FLAG elution buffer containing 0.25 mg/mL triple 996 
FLAG peptide at 4°C. The resulting immunoprecipitated material was analyzed by 997 
WB to verify a successful IP and submitted for sample preparation at the EMBL, 998 
Heidelberg Proteomics facility. Samples were prepared with the SP3 protocol68 and 999 
digested peptides analyzed by liquid chromatography followed by label free or 1000 
tandem mass tag (TMT) labeled mass spectrometry. Setd5 knock in samples were 1001 
compared against a matching background WT negative control lacking the 1002 
endogenous Setd5 FLAG-HA. Each sample at each time point was processed in 1003 
duplicates. For data analysis, label free peptides were identified and mapped using 1004 
Isobarquant software69, while the TMT labeled peptides were mapped and quantified 1005 
by MaxQuant software70 v1.5.6.5. For both datasets the raw peptide counts data 1006 
were analyzed by applying a variance stabilization normalization method with the R 1007 
package vsn (v 3.44)71. Possible batch effects were removed by fitting a linear model 1008 
to the data that explains the variance between the replicates, using R package limma 1009 
v3.3272. Coherence between samples, time points and replicates was verified by 1010 
PCA. Differential protein IP analysis was performed using R package limma; proteins 1011 
with an adjusted P value < 0.05 and log2(Fold Change) > 0 were considered to have 1012 
a significantly different binding between the endogenous tagged Setd5 and the 1013 
matching WT control. The correlation plot between the ESC stage and the NPC 1014 
stage was obtained by comparing the log2 fold change of the 2 time points. Protein-1015 
protein interaction network analysis was performed with Cytoscape73 using STRING 1016 
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database v1074 information channels and the data generated in this study. Protein-1017 
protein Interactions from STRING database with a combined score lower than 300 1018 
were discarded . Both label free and TMT labeled significant proteins were used to 1019 
generate the network. To quantify the protein-protein interaction between Setd5 and 1020 
the other proteins (black edge thickness) the log2(Fold Change) and the -1021 
log10(adjusted P value) of significantly enriched proteins from both label free and 1022 
TMT mass spectrometry experiments were scaled from 0 to 1 and then summed 1023 
together to generate a unified score value. Proteins with scaled fold change lower 1024 
than 0.048 and scaled adjusted P value lower than 0.04 were discard from the pool 1025 
of proteins used to build the networks. The log2(Fold Change) and the -1026 
log10(adjusted P value) of proteins identified both in ESCs and NPCs were summed 1027 
together to present a unique interaction value during neurodevelopment.  1028 
 1029 
Chromatin IP coupled with sequencing (ChIP-seq)  1030 
For Hdac3, Pol II and Setd5 ChIP each replicate of 100 million ESCs were harvested 1031 
and cross linked in 1.5 mM EGS in PBS  for 1h followed by 10 min cross linking in 1032 
1.5% paraformaldehyde (PFA) in PBS at RT. For H3K27ac and H4 pan acetylation 1033 
each replicate of 20 million ESCs were harvested and cross linked in 1% PFA.  1034 
Cross-linking solution was quenched with 125 mM Glycine for 5 min. Fixed cells 1035 
were spun down at 3000 rpm for 10 min at 4 °C and washed twice with ice cold 1036 
PBS freshly supplemented with complete protease inhibitor cocktail. Samples 1037 
were snap frozen in liquid nitrogen and stored at -80 °C. Briefly, chromatin was 1038 
prepared by re-suspending cross linked cells in hypotonic buffer on ice for 10 min, 1039 
followed by 35 strokes of douncing with a tissue homogenizer. The cytoplasmic 1040 
fraction was removed by gentle centrifugation and nuclear pellets were re-1041 
suspended in MNase digestion buffer. Nuclei were digested with MNase 1042 
(Worthington) at a ratio 15 µL per 50 million cells (MNase conc: 25U/µL) for 5 min at 1043 
37 °C. MNase enzymatic activity was quenched by adding EDTA/EGTA based 1044 
quenching buffer. Digested chromatin was sonicated with 3 cycles of Bioruptor Pico 1045 
sonicator (Diagenode). To separate insoluble chromatin, samples were spun down at 1046 
15,000g for 10 min at 4 °C. Soluble fragmented chromatin was used as ChIP input. 1047 
Both soluble input and precipitated pellet were resolved on agarose DNA gel to 1048 
check the digestion pattern across replicates and 5% of each chromatin input were 1049 
set aside before the IP. Each sample input was incubated with 70 µL of Invitrogen M-1050 
280 beads (Invitrogen) pre-coupled for 6h at 4°C with the specific antibody (see Life 1051 
Sciences Reporting Summary for details). Samples were incubated overnight at 4°C 1052 
and the following day beads were washed four times with LB3-100 buffer (10 mM 1053 
TRIS, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 0.1% Na-Deoxycholate, 1054 
0.5% Sarcosine) followed by one wash with LB3-500 buffer (500 mM NaCl), followed 1055 
by four washes with RIPA-250 buffer (10 mM Hepes, 250 mM LiCl, 1 1056 
mM EDTA, 0.7% Na-Deoxycholate, 1% Igepal-630), finally beads were quickly 1057 
rinsed with 10 mM Tris/1 mM EDTA buffer. Elution of the IP chromatin from the 1058 
beads was performed in elution buffer (1% SDS, 50 mM Tris, 10 mM EDTA) for 1059 
30 min at 65 °C. Eluted chromatin and ChIP inputs were reverse cross linked and 1060 
proteins were digested with proteinase K overnight at 65 °C. DNA was purified using 1061 
a PCR purification kit (QIAgen). Libraries were prepared with NEBNext Ultra II kit. 1062 
For each ChIP two biological replicates per condition (WT or ∆SET Setd5 1063 
heterozygous or homozygous) and one input per Setd5 genotype, or Setd5 WT and 1064 
Setd5-HA in the case of Setd5 ChIP, were pooled together and sequenced on an 1065 
Illumina HiSeq 2000 at EMBL, Heidelberg Gene Core facility. 1066 
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 1067 
ChIP-seq data analysis 1068 
Analysis was performed in a local installation of Galaxy75 maintained by the EMBL 1069 
Genome Biology Computational Support using mouse genome version MM10 and in 1070 
R version 3.5.0 (Bioconductor version 3.7). Data visualisations were performed using 1071 
custom-made scripts in R. The 50bp single-end reads were aligned to the mouse 1072 
genome with Bowtie version 253 using standard options (Galaxy Tool version 0.2, 1073 
sensitive preset). Reads failing to be mapped or mapping at several locations (as 1074 
identified by the XS tag set by bowtie2) were removed. Read duplicates were 1075 
identified and removed using Picard’s Mark Duplicates 1076 
(http://broadinstitute.github.io/picard). Sequencing data quality was assessed using 1077 
FastQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and the 1078 
Deeptools2 package76. Peak calling was performed using MACS version 277. See 1079 
Life Sciences Reporting Summary for peak calling details. For all experiments 1080 
MACS2 defined peaks from all conditions (WT and two mutants) were merged into a 1081 
unique non-overlapping set of 25234 peaks for Hdac3 (filtered for Qvalue < 0.001) 1082 
129203 peaks for Pol II (filtered for Qvalue < 0.001), 45842 peaks for H3K27ac 1083 
(filtered for Q-value < 0.00025) and 53778 for H4 pan acetylation (filtered for Qvalue 1084 
< 0.1) using bedtools78. Enhancers from Shen et al79 were adjusted to 2Kb (centered 1085 
on their middle point as defined in downloaded files) and lifted from mm9 to mm10 1086 
using the UCSC liftover tool. For ChIP-seq analysis at transcription start sites, TSSs 1087 
were defined using ENSEMBL version 91 considering gene start position for genes 1088 
longer than 1250bp (total number of genes 34159). Peaks falling within 2.5Kb 1089 
regions centered on TSS were considered for differential binding analysis. Peak 1090 
intersection with defined TSS resulted in 14015 peaks for Hdac3, 16152 peaks for 1091 
Pol II, and 8804 for H3K27ac. Differential analysis between mutant and WT samples 1092 
was performed using the DiffBind80 and edgeR59 packages. Differentially bound 1093 
peaks with corrected P values lower than 0.05 were selected for further analysis. 1094 
RPKM signal were calculate using the Deeptool2 “multiBamSummary” tool from 1095 
duplicates removed bam files, the count tables were than normalized to genomic 1096 
region length and sample library size, replicates were averaged and all samples 1097 
were background normalized by dividing them by the merged input RPKM.  Signal 1098 
files (bigwig format) were generated using the Deeptools2 “bam-Coverage” tool 1099 
using the “Normalize coverage to 1x” option (to correct for library size). Replicates 1100 
were averaged and input subtracted (IP minus input) using the Deeptools2 “bigwig-1101 
Compare” tool. Pol II pausing index definition was adapted from81. For each Setd5 1102 
merged replicate, input subtracted bigwig sample the average signal at TSS (-100 1103 
/+300bp) was divided by the gene body signal downstream of the TSS (+301 to 1104 
+3301bp). Genes shorter than 3.5Kb were not included in the analysis, genes with 1105 
signal lower than 1 at TSS and at the 3Kb gene body were removed from the 1106 
analysis, in total 9490 were included in the pausing index calculation. The correlation 1107 
between biological replicates was verified (Pearson’s r ~ 0.98 Pol II at TSS and 1108 
Gene body; r ~ 0.89 Hdac3 at TSS) and samples were merged for data visualisation.  1109 
 1110 
Rescue experiment 1111 
SETD5 point mutations identified in patients were obtained from the Sfari Gene 1112 
database and were selected to be equally spaced across the entire protein 1113 
sequence. We chose six mutations at R30882, K39983, T55284, E72085, R1001 and 1114 
S125882,83 all resulting in the gain of a stop codon. The WT and truncating mutations 1115 
rescue constructs were designed to have an N-terminal FLAG tagged SETD5 1116 
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followed by a P2A cleavage site and EmGFP marker. The WT human SETD5 open 1117 
reading frame and the truncated versions were cloned from the pFN21A - SETD5-1118 
HaloTag construct (Promega). All six constructs, including WT, were cloned inside 1119 
the pDonor MCS Rosa26 (addgene ID #37200) plasmid carrying 800bp homology 1120 
arms of the Rosa26 gene locus. These donor plasmids were used to generate 1121 
rescue clonal lines from ∆SET homozygous Setd5 cells. Cells were transfected with 1122 
CRISPR/Cas9 and a single guide RNA targeting the first intron of the Rosa26 gene 1123 
and the WT or truncated SETD5 rescue construct. Positive cells were FACS sorted 1124 
selecting for GFP positive events. Correct insertion of the rescue gene was 1125 
confirmed by genotyping PCRs and WBs. Different clonal cell lines carrying the 1126 
same rescue construct were considered biological replicates and were derived from 1127 
the same CRISPR/Cas9 transfection. 1128 
 1129 
Behavioural studies 1130 
Behavioural studies were carried out during the light period. Two to 3.5 month old 1131 
age- and sex-matched littermate mice were habituated to the test room for at least 1 1132 
h before each test. At least 1-week-long rest periods were given between tests. 1133 
Behavior apparatuses were cleaned between trials with 70% ethanol. All behavioural 1134 
tests were performed starting with the least aversive task first and ending with the 1135 
most aversive, and either scored automatically or by an experimenter blind to the 1136 
genotype. Both females and males were tested unless stated otherwise. When no 1137 
inter-genotypic differences were observed the data for both sexes was pooled to 1138 
avoid redundant graphs. However, in case of inter-genotypic differences, although 1139 
both male and females show essentially the same phenotype, the data for the two 1140 
sexes is reported separately. Extensive description of the behavioural studies can be 1141 
found in the Supplementary note. 1142 
 1143 
Histone acetylation  1144 
Histone extraction of the right CA hippocampal region from animals that underwent 1145 
CFC was performed employing the EpiQuik Total Histone Extraction Kit (Epigentek, 1146 
Cat. Nr. OP-0006-100), according to the manufacturer’s indications. Detailed 1147 
description of the protocol used here can be found in the Supplementary note.  1148 
Hdac3-IP and HDAC3 activity assay from adult mouse forebrain 1149 
Hdac3-IP and activity assays were performed according to a modified protocol, 1150 
previously described86.  Female 2 to 4 month old Setd5+/- and their WT littermates 1151 
were sacrificed by cervical dislocation and the hippocampus and cortex (forebrain) of 1152 
both hemispheres were rapidly dissected on ice. After washes in ice-cold 1x PBS, 1153 
tissues were homogenized in a tissue grinder in ice-cold IP-RIPA-buffer (50 mM Tris 1154 
pH 8.0, 120 mM NaCl, 0.5% NP-40 and 1 mM EDTA) with protease inhibitors 1155 
(Roche, Ref. 04 693 159 0019). Tissue lysis was allowed for 30 min on ice, followed 1156 
by 30 min centrifugation at 4°C at 13000 rpm. Supernatant was collected and protein 1157 
concentration was determined using the Pierce™ BCA Protein Assay Kit (Thermo 1158 
Fisher, Cat. no. 23225). Lysates (IP-input) were directly used for the HDAC3-IP 1159 
followed by the HDAC3 activity assay (Sigma, EPI004).  1160 
2 mg of total protein lysate was brought to 400 µl with IP-RIPA and cleared under 1161 
agitation for 1h on Protein A magnetic beads (Abcam, ab214286). Cleared lysates 1162 
were collected and split into two 200 µl (1 mg total protein) aliquots. Both samples 1163 
were incubated overnight (12-16h), at 4°C rotating, either with anti-HDAC3 1164 
conjugated protein A magnetic beads (IP+ samples, beads conjugated for 2h with 1165 
3.35 µg rabbit anti-HDAC3 primary antibody, Abcam, ab32369- for antibody details 1166 
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refer to Life Sciences Reporting Summary) or with empty beads (IP- samples). The 1167 
flow through was collected (FT samples), immune complexes washed and directly 1168 
dissolved in HDAC3 assay buffer (provided with EPI004) and equilibrated for 1h on 1169 
ice. The assay was performed according to the manufacturer’s guidelines and the 1170 
supernatant was used for flourometric measurement in polystyrene plates (Corning) 1171 
at Em/Ex=380/500 using a Synergy H1 Hybrid Reader (Biotek). HDAC3 activity was 1172 
normalized to total HDAC3 protein levels as determined by western blotting, see 1173 
above, using mouse anti-HDAC3 (Santa Cruz, sc-376957, 1:200 in 5% milk, 1x 1174 
TBST).  1175 
 1176 
Hdac3-IP and HDAC activity assay from ESCs 1177 
For Hdac3-IP, 100 million Setd5+/+ and Setd5-/- ESCs were prepared with the same 1178 
protocol as for Setd5-IP. Nuclear extract were incubated over night with Dynabeads 1179 
Protein G (Thermo Fischer, #1004D) pre-coupled with 20 µg of Hdac3 antibody 1180 
(ab7030) per IP. Beads were washed 4 times with 300mM salt wash buffer. HDAC 1181 
activity was tested using HDAC-GLOI/II assay kit (Promega, G6420, lot no 1182 
0000279650). Washed beads were resuspended in 100 µL Hdac assay buffer and 1183 
15 µL of resuspended beads were used for each reaction. All conditions were tested 1184 
in triplicates. Trichostatin A (TSA) was used as enzymatic inhibitor at 50nM final 1185 
concentration. Luminescence (400-750nm) was recorded on a 96-well plate reader 1186 
(Tecan, inifinite M1000 pro) every 2 min for 40 cycles at 25°C. Reported data is from 1187 
45 minutes after reaction start. 1188 
 1189 
Immunostaining, Nissl and fluorescence in situ hybridization (FISH) of adult 1190 
and embryonic brains and BrdU pulse-labeling  1191 
For fluorescent immunostainings and Nissl stainings in adult mice Setd5+/+ and 1192 
Setd5+/- animals were transcardially perfused, brains dissected, postfixed in 4% PFA, 1193 
dehydrated and sliced at 40 µm. For bromodeoxyuridine (BrdU) pulse labeling 1194 
pregnant females were injected with BrdU and sacrificed 2h later. Embryo heads 1195 
were dissected, fixed overnight, dehydrated and sliced at 16 µm. For FISH 1196 
experiments on adult wildtypes, brains of C57BL/6J animals were dissected, 1197 
immediately frozen in O.C.T, sectioned at 20 µm and stored at -80°C. For detailed 1198 
experimental protocols of imaging and quantifications refer to the Supplementary 1199 
note, for details about primary antibodies used refer to the Life Sciences Reporting 1200 
Summary. 1201 
 1202 
Hippocampal slice preparation and electrophysiology 1203 
Transverse dorsal hippocampal slices (300 µm) were prepared from P21-P24 male 1204 
littermates. Slices were recovered for 1h at 33 °C, and then at RT (21-23 °C) in 1205 
carbogenated artificial cerebrospinal fluid (aCSF) containing (in mM): 130 NaCl, 1206 
2.75 KCl, 1.1 NaH2PO4, 28.82 NaHCO3, 11 glucose, 1.43 MgSO4, 2.5 CaCl2, 5 Na 1207 
ascorbate and 3 Na pyruvate (~320 mOsm, 7.2–7.4 pH). Filed potential in the CA1 1208 
stratum radiatum were generated and recorded using aCSF-filled electrodes. Signals 1209 
were amplified by a Multiclamp 700B amplifier (Axon Instruments/Molecular 1210 
Devices), and then digitized using Digidata 1550A (Molecular Devices). Extended 1211 
protocol is described in the supplementary note. 1212 
  1213 
Data analysis 1214 
All data analysis was performed blind to the genotype. Data exclusion criteria have 1215 
always been pre-established and respected throughout data acquisition and 1216 
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analysis. Examples of exclusion criteria: death of an animal during data acquisition 1217 
lead to the exclusion of its littermate sibling; no LTP observable in the control mouse 1218 
(experimental problems assumed) - both the control and the sibling mutant removed 1219 
from data sets; one control-mutant pair was removed from the LTP data set after 1220 
noticing that in the case of the mutant, the recording had been performed in a slice 1221 
from the intermediate hippocampus, and not dorsal, like all other. We discarded all 1222 
data resulting from experiments for protocol optimisation, because the working 1223 
protocol was not respected. No outlier was removed from any data set with the 1224 
exception of one sample in the RNA-sequencing analysis (1h, WT) that clustered 1225 
clearly away from all other samples (clustering by euclidean sample distance and 1226 
PCA) during the preliminary quality assessment. 1227 
 1228 
Statistics 1229 
Statistical analyses were performed using R, Origin Software (Origin Inc) and 1230 
GraphPad Prism. Shapiro–Wilk test was used to evaluate normal distribution and 1231 
Levene’s test for equal variance of all data sets. Parametric data were analyzed for 1232 
significance using one-way or two-way ANOVA with Bonferroni post-hoc test, using 1233 
*P < 0.05, **P < 0.01, ***P<0.001, and presented as scatter plots and 1234 
mean ± standard error of the mean (SEM), unless otherwise specified.  Data sets 1235 
with non-normal distributions and/or unequal variance were analyzed using the 2-1236 
tailed Mann-Whitney U test or Kruskal-Wallis test and presented as boxplots and 1237 
individual data points. Adjustment for multiple comparisons were made using post-1238 
hoc tests Bonferroni (parametric data) or Dunn (non-parametric data). The data met 1239 
the assumptions of the statistical test used and were generally evaluated in terms of 1240 
distribution and variances, as seen in Supplementary Table 1. Although we report to 1241 
have used two-way ANOVA with repeated measures and Kruskal-Wallis tests using 1242 
corrections for multiple comparisons, our data sets were also evaluated in a 1243 
generalized linear model in R with similar outcomes. Experiments were replicated at 1244 
least three times (including behavioural experiments, which were performed on at 1245 
least three different cohorts). 1246 
Sample size calculation: The sample size was predetermined using the tool provided 1247 
here: http://biomath.info/power/ttest.htm. In addition, calculated sample size was 1248 
compared against sizes known from previous experience to yield high power to 1249 
detect specific effects for each experiment. Accordingly, in some of the tests we 1250 
decided to use less animals (<30), since the generated numbers were ethically 1251 
unacceptably high.  1252 
Randomization: For in vivo experiments, mice were chosen based on genotypes. 1253 
Sex-matched animal pairs of control-mutant siblings from the same litters were 1254 
compared to decrease variance due to age, environment and genetic background87. 1255 
At least 5 litters were used in each behavioral test.  1256 
 1257 
Life Sciences Reporting Summary: Further information on experimental design is 1258 
available in the Life Sciences Reporting Summary.  1259 
Data availability: The data that support the findings of this study are available from 1260 
the corresponding author upon reasonable request.  1261 
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